Close
Virginia Kaklamani, M.D.
NOTE : If you're an existing patient of Dr. Kaklamani, please connect via MyChart
-
About Me
About Virginia Kaklamani, M.D.
Dr. Kaklamani is professor of medicine in the Division of Hematology and Medical Oncology at the University of Texas Health Sciences Center San Antonio and is the leader of the breast cancer program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson. Dr. Kaklamani completed her medical training with honors at the University of Athens and her residency in internal medicine at Newton-Wellesley Hospital in Boston. She completed her fellowship in hematology/oncology at Northwestern University. She also received a Master of Science in Clinical Investigation from Northwestern University. She was head of the Translational Breast Cancer Program at Northwestern University and co-director of the cancer genetics program at the same institution. Dr. Kaklamani has also served as the associate director for clinical research at UT Health San Antonio. Her research interests include designing clinical trials with targeted agents. Dr. Kaklamani has also identified several genetic mutations that link obesity and breast cancer.
Dr. Kaklamani was also named one of San Antonio’s Top Doctors for Women and San Antonio’s Top Doctors 2021.
Gender
- Female
Languages Spoken
- English
- Greek
Virginia Kaklamani | Breast Oncology
Breast Cancer is a disease we all need to fight together
-
Credentials
Credentials
Positions
- Professor of Medicine, University of Texas Health Science Center San Antonio
- Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
- A.B. Alexander Distinguished Chair in Oncology
- Leader, Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center
- Co-Director, Cancer Genetics Program, UT Health San Antonio MD Anderson Cancer Center
Certifications
- American Board of Internal Medicine Hematology Oncology
Education
- Medical School: National & Kapodistrian University of Athens, Athens, Greece
- Residency: Athens University Medical School, Athens, Greece
- Graduate School: Northwestern University, Chicago, Illinois
-
Locations & Contact
Locations & Contact
Dr. Kaklamani is very, very knowledgeable, very polite. She makes you feel comfortable in the office talking about difficult topics. I would highly recommend her and appreciate her greatly. Thank you.
Patient
-
Research & Publications
Research & Publications
BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association
Waisbren J., Uthe R., Siziopikou K., Kaklamani V.
BMJ Case Rep. 2015 Jul 6;2015. pii: bcr2014208830. doi: 10.1136/bcr-2014-208830. PubMed PMID: 26150619.
National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.
Daly M.B., Pilarski R., Axilbund J.E., Buys S.S., Crawford B., Friedman S., Garber J.E., Horton C., Kaklamani V., Klein C., Kohlmann W., Kurian A., Litton J., Madlensky L., Marcom P.K., Merajver S.D., Offit K., Pal T., Pasche B., Reiser G., Shannon K.M.,
J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38. PubMed PMID: 25190698
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
Kaklamani V.G., Jeruss J.S., Hughes E., Siziopikou K., Timms K.M., Gutin A., Abkevich V., Sangale Z., Solimeno C., Brown K.L., Jones J., Hartman A.R., Meservey C., Jovanovic B., Helenowski I., Khan S.A., Bethke K., Hansen N., Uthe R., Giordano S., Rosen S
Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26. PubMed PMID: 26006067.
-
Clinical Trials
Clinical Trials
Type of Cancer
Breast
ClinicalTrials.gov Identifier
NCT02068092
Principal Investigator
Virginia Kaklamani M.D.
A PILOT STUDY OF HYDROXYTYROSOL, A COMPONENT OF OLIVE OIL FOR BREAST CANCER PREVENTION IN WOMEN AT HIGH RISK OF BREAST CANCER (CTMS# 16-0068)
This is a single-arm, pilot breast cancer prevention study of hydroxytyrosol in women at increased risk of breast cancer. Our primary study endpoint will be defined as proportion of women who exhibit a 10% absolute reduction in mammographic density at one-year of follow-up (Cuzick JNCI 2011). For each of the post and pre-menopausal group of women, we will assume under the null hypothesis that 25%…
Type of Cancer
Breast
ClinicalTrials.gov Identifier
NCT02488967
Principal Investigator
Virginia Kaklamani M.D.
NRG-BR003, A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (CTMS# 15
Patients will be randomized to receive doxorubicin/cyclophosphamide followed by paclitaxel (AC WP) or doxorubicin/cyclophosphamide followed by paclitaxel with carboplatin (AC WP + Carboplatin). Treatment assignment will be balanced with respect to number of positive nodes (0, 1-3, 4-9, 10+) and BRCA mutation status (positive; negative or unknown) with applying a biased-coin minimization…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations (CTMS# 15-2081)
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for whom no standard treatment exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) (CTMS# 15-2082)
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for whom no standard treatment exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol C1: EAY131-C1: Crizotinib in Patients with Tumors with MET Amplification (CTMS# 16-0064)
The purpose of this study is to test any good and bad effects of the study drug called crizotinib in patients whose cancer has MET genetic changes.
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH 1) Mutations (CTMS# 16-0030)
The purpose of this study is to test any good and bad effects of the study drug GDC-0449 (vismodegib) in patients whose cancer has genetic changes in the genes Smoothened and Patched 1.
Type of Cancer
Breast
ClinicalTrials.gov Identifier
NCT03329131
Principal Investigator
Virginia Kaklamani M.D.
Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy (CTMS# 17-0033)
This is a therapeutic study investigating the use of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy (CIPN) and associated nail toxicities. The therapeutic intervention will involve patients wearing an Elasto-Gel cold glove and sock on their non-dominant hand and foot. The dominant side will not have the glove and sock applied and will act as an internal control. The…
Type of Cancer
Breast
ClinicalTrials.gov Identifier
NCT02980341
Principal Investigator
Virginia Kaklamani M.D.
Phase 1/2, Multicenter, Nonrandomized, Open-Label, Multiple Dose First-In-Human Study of U3-1402, In Subject with HER3 Positive Metastatic Breast Cancer (CTMS# 18-0052)
This is a Phase 1/2, multicenter, non-randomized, open-label, multiple dose, first in human study of U3-1402 in subjects with human epidermal growth factor receptor 3 (HER3) positive metastatic breast cancer. This study consists of 3 parts: Dose Escalation, Dose Finding, and Dose Expansion. In the Dose Escalation Part, subjects with HER3 positive metastatic breast cancer who have been refractory…
ClinicalTrials.gov Identifier
NCT02513472
Principal Investigator
Virginia Kaklamani M.D.
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination with Pembrolizumab in Subjects with Metastatic Triple-Negative Breast Cancer (mTNBC) (CTMS# 15-2079)
<p>This is an open-label, single-arm, multicenter, Phase 1b/2 study of eribulin mesylate in combination with pembrolizumab in participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.</p>
ClinicalTrials.gov Identifier
NCT02988986
Principal Investigator
Virginia Kaklamani M.D.
Open Label, Phase II Trial Of Neoadjuvant TAK-228 Plus Tamoxifen In Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor Type 2 (HER2)-Negative Breast Cancer (CTMS# 17-0070)
<p>This is an open label phase II clinical trial to determine the efficacy, toxicity, and safety of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast cancer.</p>
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
EAY131-B, Molecular Analysis for Therapy Choice (MATCH), MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations (CTMS# 15-2107)
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss (CTMS# 15-2110)
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol I: GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA Mutation but without KRAS Mutation or PTEN Loss (CTMS# 16-0023)
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients with Tumors with NF1 Mutations (CTMS# 16-0028)
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations (CTMS# 16-0032)
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1B: EAY131-Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC (CTMS# 16-0067)
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol W: EAY131-W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway (CTMS# 16-0065)
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
Molecular Analysis for Therapy Choice (MATCH) / MATCH Treatment Subprotocol H: EAY131-H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, and Colorectal Adenocarcin
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
ClinicalTrials.gov Identifier
NCT03122444
Principal Investigator
Virginia Kaklamani M.D.
A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Imipramine on Triple Negative Breast Cancer (CTMS# 17-0037)
<p>Comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.</p>
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations (CTMS# 17-0027)
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC (CTMS# 17-0025)
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
ClinicalTrials.gov Identifier
NCT02465060
Principal Investigator
Virginia Kaklamani M.D.
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations (CTMS# 17-0026)
<p>This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as…
Type of Cancer
Breast
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, MULTICENTER TRIAL (EMERALD) CTMS#: 19-0013
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated w
Type of Cancer
Breast
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201A, An Anti-HER2-Antibody Drug Conjugate, Versus Ado-Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated
Type of Cancer
Other
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
EAY131-Z1G, Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result CTMS# 19-0054
Type of Cancer
Other
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
EAY131-Z1H, Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC CTMS#: 19-0055
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Lea
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani M.D.
AN OPEN LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN LA ROCHE LTD SPONSORED ATEZOLIZUMAB STUDY (IMBRELLA B)